QM · rank #6 · 2026-07-20
LQDA
NASDAQ · $6.69B (USD)
The exact numbers the algorithm saw.
| Momentum 12-1 Return from 12 months ago to 1 month ago. | +439.64% |
|---|---|
| ROE TTM Return on equity, trailing 12 months. | +28.2% |
| Profit margin Net profit margin, trailing 12 months. | +7.7% |
| Market cap (USD) Size filter: > $500M required. | $6.69B |
| Anchor (recent) Close on 2026-06-18 | $71.07 |
| Anchor (far) Close on 2025-06-20 | $13.17 |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
LQDA is a commercial-stage specialty pharma company selling YUTREPIA for pulmonary arterial hypertension and PH-ILD, with recent Q1 2026 sales and profitability surging after FDA approval in 2025.
Rationale
The signal fits a quality-momentum setup because the stock shows strong 12-1 momentum alongside improving fundamentals, including high ROE, positive margins, and a large step-up in revenue and net income from YUTREPIA launch execution.
Material risks
- 1Ongoing United Therapeutics patent litigation, especially around the ’782 patent, could still lead to an injunction or commercialization restriction that would directly hit the core revenue driver.
- 2YUTREPIA faces entrenched competition from Tyvaso and Tyvaso DPI, leaving pricing and share gains exposed if uptake slows or rival formulations gain traction.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 1 of 3 voted to proceed.